Drugs Containing Excipient (Inactive Ingredient) HYDROGENATED PALM KERNEL OIL

« Back to Dashboard

Branded drugs containing HYDROGENATED PALM KERNEL OIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sun Pharmaceutical Industries Inc	FEVERALL	acetaminophen	51672-2114	HYDROGENATED PALM KERNEL OIL
Sun Pharmaceutical Industries Inc	FEVERALL	acetaminophen	51672-2115	HYDROGENATED PALM KERNEL OIL
Sun Pharmaceutical Industries Inc	FEVERALL	acetaminophen	51672-2116	HYDROGENATED PALM KERNEL OIL
Taro Pharmaceuticals USA Inc	FEVERALL	acetaminophen	51672-2117	HYDROGENATED PALM KERNEL OIL

Generic drugs containing HYDROGENATED PALM KERNEL OIL excipient

Company	Ingredient	NDC	Excipient
Actavis Pharma Inc	miconazole nitrate	0472-1736	HYDROGENATED PALM KERNEL OIL
Actavis Pharma Inc	miconazole nitrate	0472-1738	HYDROGENATED PALM KERNEL OIL
Padagis US LLC	prochlorperazine	0574-7226	HYDROGENATED PALM KERNEL OIL
Strategic Sourcing Services LLC	miconazole nitrate	49348-833	HYDROGENATED PALM KERNEL OIL

Hydrogenated Palm Kernel Oil Excipient Market Dynamics and Financial Trajectory

Last updated: August 20, 2026

Hydrogenated palm kernel oil is a specialty lipid excipient used mainly in solid-dose formulations, suppository bases, lipid-based delivery systems, and controlled-release products. Its market is driven by pharmaceutical-grade supply reliability, melting-point control, oxidation stability, and regulatory documentation rather than by large pharmaceutical volumes.

The product has no consistently reported standalone market size or public-company revenue line. Financial performance is therefore best assessed through palm-kernel feedstock prices, specialty oleochemical margins, pharmaceutical excipient qualification cycles, and substitution risk from hydrogenated vegetable oils, hard fats, glyceryl esters, waxes, and synthetic lipids.

What is hydrogenated palm kernel oil used for in pharmaceuticals?

Hydrogenated palm kernel oil is a hardened fraction or derivative of palm-kernel oil in which unsaturated fatty acids are reduced through hydrogenation. The process increases solid-fat content, oxidative stability, and melting-point control.

Pharmaceutical applications include:

Application	Functional role	Commercial relevance
Suppositories and pessaries	Melting base that softens or melts at body temperature	Established use in rectal and vaginal dosage forms
Tablet formulations	Binder, lubricant, anti-adherent, or hydrophobic release modifier	Moderate relevance, often formulation-specific
Lipid-based drug delivery	Matrix former and carrier for poorly soluble active ingredients	Growth opportunity but technically selective
Controlled-release tablets	Hydrophobic barrier that slows liquid penetration	Relevant where release-rate control is required
Soft capsules and semisolids	Structuring lipid or consistency modifier	Smaller application segment
Nutraceuticals	Carrier and texture modifier	Larger volume potential but lower pharmaceutical qualification burden

Commercial products may be sold under names such as hard fat, hydrogenated palm kernel glycerides, or pharmaceutical-grade hydrogenated vegetable oil. Product identity depends on fatty-acid composition, degree of hydrogenation, triglyceride profile, particle size, and excipient specifications.

Hydrogenated palm kernel oil should not be treated as interchangeable with all hard fats. Suppository performance depends on polymorphism, congealing behavior, brittleness, viscosity, drug partitioning, and release characteristics. A substitution can require reformulation and stability studies.

How large is the hydrogenated palm kernel oil excipient market?

No authoritative public source reports a separate global market value for hydrogenated palm kernel oil used as a pharmaceutical excipient. Market reports typically aggregate it into specialty excipients, hard fats, lipid excipients, suppository bases, or oleochemicals.

The addressable market is likely small relative to mainstream excipients such as microcrystalline cellulose, lactose, starch, magnesium stearate, or polyethylene glycol. Its economics are more consistent with a specialty ingredient market:

• Feedstock is a commodity-linked palm-kernel product.
• Processing, purification, and documentation create the pharmaceutical value premium.
• Volumes are modest compared with food, cosmetics, and industrial oleochemicals.
• Customer qualification creates switching friction.
• Pricing depends on grade, packaging, region, certificate package, and supply assurance.
• Contracted or validated pharmaceutical sales are more stable than spot commodity sales.

The pharmaceutical segment is structurally higher margin than food-grade hydrogenated oil, but the margin is constrained by competing hard fats and the availability of alternative excipient platforms.

What factors are driving demand?

Growth in lipid-based drug delivery

Poor aqueous solubility remains a formulation problem for many small-molecule drugs. Lipid excipients can improve wetting, solubilization, dispersion, and absorption. Hydrogenated palm kernel oil is relevant where a solid lipid matrix or hydrophobic barrier is required.

Demand is strongest in products requiring:

• Modified release
• Improved oral bioavailability
• Solid lipid nanoparticles
• Lipid microparticles
• Taste masking
• Moisture protection
• Thermal or oxidative stability

The excipient is not a universal solubilizer. Its value is highest when the formulation requires a solid lipid with a defined melting range and reproducible release behavior.

Suppository and local-delivery products

Hard-fat suppository bases remain commercially relevant in markets where rectal and vaginal dosage forms are established. Hydrogenated palm kernel oil and related hard fats can provide controlled melting and acceptable mold release.

This segment is mature rather than high growth. Demand is supported by generic suppositories, hospital products, local anesthetic formulations, laxatives, antipyretics, and gynecological products.

Generic-drug development

Generic manufacturers often seek excipients that reproduce the performance of an existing reference product. Once a lipid excipient is embedded in a validated formulation, replacement may trigger comparative dissolution, stability, bioequivalence, or process-validation work.

That creates a qualification barrier. It does not create absolute exclusivity because competing excipients may be accepted through a new formulation-development program.

Regional pharmaceutical manufacturing

India, China, Southeast Asia, Latin America, and parts of the Middle East are important demand centers for cost-sensitive generic production. Local excipient sourcing can reduce freight and inventory costs, but pharmaceutical customers still require consistent specifications, GMP controls, traceability, and regulatory support.

What factors are constraining the market?

Palm-kernel feedstock volatility

Palm-kernel oil prices are influenced by palm-oil production, kernel availability, crushing economics, oleochemical demand, weather, labor, energy, freight, and competing demand from cosmetics and food manufacturers. Palm-kernel oil generally trades with a different supply-demand balance from palm oil because it is obtained from the kernel rather than the fruit mesocarp.

A specialty excipient producer may not be able to pass through a sharp feedstock increase immediately. This creates margin compression during short-term price spikes, particularly where customer contracts are annual or qualification rules limit supplier changes.

Competition from alternative excipients

Key substitutes include:

• Hydrogenated vegetable oils from soybean, cottonseed, or other sources
• Cocoa-butter substitutes and hard fats
• Glyceryl behenate
• Glyceryl palmitostearate
• Stearic acid derivatives
• Carnauba wax and beeswax
• Microcrystalline wax
• Polyethylene glycol
• Synthetic and semi-synthetic lipid carriers

The substitute threat is highest in tablet lubrication and matrix formulations. It is lower where the product has been validated as a suppository base and the formulation depends on a narrow melting or solidification profile.

Sustainability and customer-procurement requirements

Palm-derived ingredients face scrutiny over deforestation, traceability, labor conditions, and land-use impacts. Pharmaceutical customers increasingly request documentation under responsible-sourcing policies, even when the ingredient represents a small portion of the finished product cost.

Certification can increase procurement eligibility but may raise cost and reduce sourcing flexibility. Relevant systems include RSPO certification and customer-specific traceability requirements. Certification does not automatically establish pharmaceutical suitability.

Regulatory and quality expectations

The product must be controlled as a pharmaceutical excipient when sold for drug manufacturing. Typical requirements include:

• Identity and purity testing
• Fatty-acid and triglyceride profile
• Melting or congealing range
• Acid value and peroxide value
• Water content
• Residual solvents, where applicable
• Elemental impurities
• Microbial limits
• Allergen and cross-contamination controls
• Change-control procedures
• Stability data
• GMP and quality-system documentation

The FDA does not generally approve excipients through a standalone approval pathway equivalent to an active pharmaceutical ingredient. Drug manufacturers remain responsible for excipient suitability in the finished product. The FDA Inactive Ingredient Database can provide precedent for certain excipient uses, but it does not substitute for formulation-specific assessment.[1]

Who supplies pharmaceutical-grade hydrogenated palm kernel oil?

The supply base is fragmented across oleochemical manufacturers, hard-fat producers, excipient specialists, and regional distributors. Public disclosures often identify broad product families rather than revenue from hydrogenated palm kernel oil specifically.

Relevant supplier categories include:

Supplier category	Typical capability	Competitive advantage
Integrated palm and oleochemical groups	Feedstock access, hydrogenation, fractionation, global logistics	Cost and supply security
Specialty excipient manufacturers	Pharmaceutical documentation and dosage-form expertise	Qualification support
Hard-fat producers	Suppository-base formulation and melting-profile control	Application know-how
Regional distributors	Inventory, regulatory support, local service	Shorter lead times
Custom manufacturers	Specification tailoring and private-label supply	Flexibility for niche products

Important commercial distinctions include whether the supplier controls palm-kernel feedstock, operates dedicated pharmaceutical equipment, provides DMF or equivalent regulatory support, and maintains multiple manufacturing sites.

A low-cost producer without pharmaceutical documentation is not a direct substitute for a qualified excipient supplier. Conversely, a fully qualified producer may face pricing pressure if customers can qualify a second source.

How does the financial trajectory compare with commodity palm-kernel oil?

The financial trajectory has three layers:

Feedstock layer

Revenue and gross margin are exposed to palm-kernel oil and hydrogenation costs. Commodity cycles can cause substantial month-to-month or quarter-to-quarter volatility. Feedstock access and inventory policy are important sources of competitive advantage.

Processing layer

Hydrogenation, fractionation, purification, milling, and packaging create the conversion margin. This margin depends on plant utilization, energy prices, batch size, product mix, and quality-control requirements.

Pharmaceutical layer

Pharmaceutical-grade sales generate the highest value per kilogram because customers pay for documentation, consistency, regulatory support, and qualification continuity. The premium is limited by the small formulation volumes and availability of substitutes.

A practical financial model is:

Variable	Directional effect on supplier economics
Palm-kernel oil price	Raises cost of goods; negative unless passed through
Hydrogen and energy costs	Raises conversion cost
Pharmaceutical-grade share	Increases average selling price and margin
Plant utilization	Improves fixed-cost absorption
Customer qualification duration	Supports retention after approval
Second-source qualification	Increases price pressure
Sustainability certification	Raises cost but improves access to multinational buyers
Freight and packaging	Particularly important for exports and small lots
Product customization	Increases margin but reduces manufacturing scale

There is no defensible basis for assigning a standalone revenue forecast without supplier-level segment reporting. The more reliable conclusion is that revenue should grow gradually with specialty excipient demand, while profit will remain cyclical because feedstock costs can move faster than pharmaceutical pricing.

What is the patent strength of hydrogenated palm kernel oil?

The base material has limited standalone patent protection. Hydrogenation of vegetable oils and the use of hardened fats in dosage forms are established technologies. A supplier is unlikely to maintain a durable composition-of-matter monopoly over ordinary pharmaceutical-grade hydrogenated palm kernel oil.

Protection may exist around:

• A defined triglyceride or fatty-acid composition
• A narrow melting-point distribution
• A particular fractionation process
• Low-peroxide or low-impurity processing
• Particle engineering
• Spray-congealed or micronized forms
• A controlled-release formulation
• A specific suppository composition
• A drug-excipient combination
• A manufacturing process with improved stability

These rights generally protect a product specification or formulation, not the entire hydrogenated palm kernel oil market. Freedom-to-operate analysis must therefore examine the supplier’s product specifications, formulation patents, process claims, and jurisdictional coverage.

What regulatory barriers affect market entry?

Market entry is commercially feasible but slow. A new supplier must establish pharmaceutical-grade manufacturing and win customer qualification.

Key barriers are:

1. Demonstrating consistent raw-material sourcing.
2. Establishing validated hydrogenation and purification processes.
3. Maintaining batch-to-batch control over melting and solid-fat characteristics.
4. Producing a complete excipient quality package.
5. Passing customer audits.
6. Supporting stability and formulation studies.
7. Establishing global regulatory documentation.
8. Qualifying packaging and shipping conditions.
9. Managing change control without disrupting approved products.

The main barrier is not patent exclusivity. It is the time and cost required for formulation customers to validate a second source.

What generic-entry and biosimilar risks exist?

Hydrogenated palm kernel oil is an excipient, not a biologic active ingredient. Biosimilar risk is therefore not directly applicable. The relevant competitive risk comes from generic-drug formulation development and alternative excipient selection.

Generic entry can increase excipient demand when manufacturers reproduce lipid-based or suppository formulations. It can also reduce demand if generic developers redesign the formulation with a cheaper or more readily available excipient.

The strongest defense against substitution is a validated formulation with difficult-to-reproduce performance. The weakest position is a commodity-like tablet lubricant application with broad functional alternatives.

What licensing deals and litigation affect the market?

Publicly disclosed licensing deals and patent litigation focused specifically on hydrogenated palm kernel oil as a pharmaceutical excipient are limited. Most commercial arrangements are private supply agreements, distribution contracts, quality agreements, and formulation-development relationships.

Litigation risk is more likely to arise from:

• Product liability
• Contamination or specification failures
• Supply interruption
• Contractual quality disputes
• Patent claims covering a drug formulation
• Misrepresentation of pharmaceutical grade
• Sustainability or chain-of-custody claims

The absence of major public litigation does not eliminate contractual risk. Pharmaceutical customers may impose substantial obligations for notification, recall support, audit rights, indemnification, and manufacturing changes.

How does hydrogenated palm kernel oil compare with competing lipid excipients?

Attribute	Hydrogenated palm kernel oil	Glyceryl behenate	PEG-based excipient	Synthetic lipid
Feedstock basis	Palm-kernel-derived	Fatty-acid/glyceride-based	Petrochemical or synthetic	Synthetic or semi-synthetic
Primary strength	Hard-fat structure and melting control	Matrix formation and lipid functionality	Solubility and processing flexibility	Tunable performance
Cost position	Generally competitive	Often higher in specialty grades	Broad range	Usually higher
Sustainability scrutiny	High	Depends on feedstock	Different environmental profile	Process-dependent
Suppository suitability	Strong for hard-fat systems	Formulation-dependent	Usually less direct	Product-specific
Patent exposure	Low for base material	Low to moderate by formulation	Moderate in specialized systems	Potentially higher
Qualification burden	Moderate to high	Moderate to high	Moderate	High for novel systems

Hydrogenated palm kernel oil competes most effectively where a formulation requires a hard, stable lipid with defined thermal behavior at a competitive cost.

What is the outlook for revenue and margins?

The base-case outlook is steady growth in pharmaceutical-grade demand, with uneven profitability.

Period	Expected market condition
Near term	Feedstock and energy volatility; cautious inventory management
Medium term	Gradual growth from lipid delivery, generics, and regional pharmaceutical production
Longer term	Higher documentation and sustainability costs; continued substitution pressure

Revenue upside is strongest for suppliers that move from bulk hydrogenated oil into branded excipient systems, prequalified suppository bases, micronized powders, or formulation support. Margin upside is weaker for suppliers selling undifferentiated material under annual contracts.

The most attractive strategy is vertical integration combined with pharmaceutical specialization. The least attractive strategy is relying on spot sales of a commodity-like grade without a qualification moat.

Key Takeaways

• Hydrogenated palm kernel oil is a specialty pharmaceutical excipient, not a separately transparent public market.
• The main applications are suppository bases, lipid matrices, controlled-release systems, and selected tablet formulations.
• Financial performance is driven by palm-kernel feedstock costs, hydrogenation economics, plant utilization, and pharmaceutical-grade premiums.
• Patent protection for the base material is generally limited; formulation and process patents may create narrower barriers.
• Customer qualification and regulatory documentation are more important than standalone patent exclusivity.
• Demand should expand gradually, but margins remain exposed to feedstock volatility and substitution by other hard fats and lipid excipients.
• Biosimilar risk is not directly relevant. Generic formulation activity is the primary volume and substitution driver.
• Suppliers with integrated feedstock access, validated pharmaceutical manufacturing, sustainability credentials, and application support have the strongest commercial position.

FAQs

Is hydrogenated palm kernel oil listed in the FDA Inactive Ingredient Database?

Some palm-derived and hydrogenated lipid excipients may have FDA inactive-ingredient precedent under specific names, routes, and dosage forms. Database entries must be checked by exact ingredient identity and use level because similar hard fats are not automatically interchangeable.[1]

Is hydrogenated palm kernel oil suitable for vegan pharmaceuticals?

The ingredient is plant-derived, but the finished excipient may not satisfy every vegan standard. Processing aids, capsule components, manufacturing-line controls, and supplier certifications must be assessed separately.

Does hydrogenated palm kernel oil contain trans fat?

Hydrogenation can create trans fatty acids depending on the process and degree of hydrogenation. Pharmaceutical specifications should identify fatty-acid composition and control relevant impurities. Full hydrogenation generally reduces unsaturation but does not make process history irrelevant.

Can hydrogenated palm kernel oil replace cocoa butter in suppositories?

It can be used as a cocoa-butter alternative in some suppository systems, but substitution requires evaluation of melting behavior, polymorphism, drug release, mold release, storage stability, and bioavailability.

What is the main investment risk in pharmaceutical hydrogenated palm kernel oil?

The main risk is margin compression from volatile palm-kernel feedstock prices combined with limited ability to increase prices after customers qualify a formulation. The strongest offset is a high share of validated pharmaceutical-grade and customized products.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. International Pharmaceutical Excipients Council. (2017). The Joint IPEC-PQG Good Manufacturing Practices Guide for Pharmaceutical Excipients. IPEC Federation.
3. International Pharmaceutical Excipients Council. (2022). IPEC Certificate of Analysis Guide for Pharmaceutical Excipients. IPEC Federation.
4. European Medicines Agency. (2019). Guideline on the formalised risk assessment for ascertaining the appropriate good manufacturing practice for excipients of medicinal products for human use. EMA.
5. Roundtable on Sustainable Palm Oil. (n.d.). RSPO Principles and Criteria. https://rspo.org
6. U.S. Department of Agriculture, Foreign Agricultural Service. (2024). Oilseeds: World Markets and Trade. USDA.
7. Malaysian Palm Oil Board. (n.d.). Malaysian palm oil industry statistics. https://mpob.gov.my